AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Probable helicase senataxin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q7Z333

UPID:

SETX_HUMAN

Alternative names:

Amyotrophic lateral sclerosis 4 protein; SEN1 homolog; Senataxin

Alternative UPACC:

Q7Z333; A2A396; B2RPB2; B5ME16; C9JQ10; O75120; Q3KQX4; Q5JUJ1; Q68DW5; Q6AZD7; Q7Z3J6; Q8WX33; Q9H9D1; Q9NVP9

Background:

Senataxin, known as Probable helicase senataxin and alternatively named Amyotrophic lateral sclerosis 4 protein and SEN1 homolog, plays a pivotal role in RNA metabolism, genomic integrity, and transcription regulation. It is essential for mRNA splicing, R-loop RNA-DNA hybrid resolution, and DNA damage response. Senataxin's involvement in circadian rhythm regulation and neurite outgrowth underscores its multifaceted biological significance.

Therapeutic significance:

Senataxin is linked to Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 (SCAN2) and Amyotrophic lateral sclerosis 4 (ALS4), diseases characterized by progressive neurodegeneration. Understanding Senataxin's role could pave the way for novel therapeutic strategies targeting these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.